Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

Advice from successful people is inherently flawed because it ignores the role of luck and timing. A more accurate approach is to study failures—the metaphorical planes that didn't return. Understanding why most people *don't* succeed provides a more robust framework for navigating risk than simply copying a survivor's path.

Quoting Amgen founder George Ratham, the podcast guest emphasizes that a true biotech company must "walk through the valley of death"—experiencing near-bankruptcy multiple times. This trial by fire is not a sign of failure but a necessary process for building the character required for ultimate success.

A venture capitalist's first question to a founder is about a major failure. An inability to answer ends the meeting, as it signals a lack of experience in confronting and overcoming adversity, a crucial skill for leading a startup.

When a biotech company shutters, it's not a total loss. The scientific dead ends it uncovers prevent others from wasting resources on the same path. These "failures" enrich the ecosystem with crucial knowledge and release experienced talent back into the market.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.

Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.

Alex Rubalcava reveals that the most valuable advice he gives founders comes directly from past mistakes in his portfolio that cost millions of dollars. This "scar tissue" provides a hard-won perspective on what not to do—insights that are impossible to gain from successes alone.

While success is celebrated publicly, some of the best leadership happens privately when a CEO makes the tough, candid call to shut down a program or company due to unfavorable data. This "truth-seeking" decision, often against their personal interest, is a hallmark of excellence.